Over 150 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions
40 presentations and case studies focused on the key issues in drug discovery and medicinal chemistry
4 Interactive Streams:
- Target Based Discovery
- Screening & Assays: Enabling Technologies
- Discovery 91AV & Drug Design
- Supporting Innovation: Translational Approaches & Informatics Tools
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities.
The drug discovery landscape is changing rapidly. With the cost of bringing a drug to market rising, researchers are seeking innovative ways to increase the efficiency of their R&D pipelines. On the first day of our Drug Discovery USA Congress our expert panel of speakers will address the current strategies for directed discovery, including the resurgence of phenotypic screening and comparing its utility with target based discovery. Our renowned speakers will explore novel peptide drug discovery, strategies for target selection and incorporating genomic technologies into discovery research. Day one also features an exciting stream covering the latest screening and assay technologies, such as novel stem cell assays, exciting new phenotypic screening strategies and how to use stem and primary cells for physiologically relevant disease models.
The pharma industry is seeing an increased focus on strengthening data and knowledge management in R&D pipelines to make the most of discovery data. Researchers are seeking new techniques to manage complex early stage discovery portfolios and for library optimisation. On day two our Congress features an exciting stream dedicated to supporting innovation with informatics tools in which we will explore new data analysis and integration platforms, as well as ideas for efficient data exchange and pre-competitive collaboration. Day two will also host discussions about the latest research in the discovery chemistry field, with exciting case studies covering computational tools for gene editing and drug design as well as fragment based drug discovery case studies.
40 presentations and case studies focused on the key issues in drug discovery and medicinal chemistry
4 Interactive Streams:
- Target Based Discovery
- Screening & Assays: Enabling Technologies
- Discovery 91AV & Drug Design
- Supporting Innovation: Translational Approaches & Informatics Tools
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities.
The drug discovery landscape is changing rapidly. With the cost of bringing a drug to market rising, researchers are seeking innovative ways to increase the efficiency of their R&D pipelines. On the first day of our Drug Discovery USA Congress our expert panel of speakers will address the current strategies for directed discovery, including the resurgence of phenotypic screening and comparing its utility with target based discovery. Our renowned speakers will explore novel peptide drug discovery, strategies for target selection and incorporating genomic technologies into discovery research. Day one also features an exciting stream covering the latest screening and assay technologies, such as novel stem cell assays, exciting new phenotypic screening strategies and how to use stem and primary cells for physiologically relevant disease models.
The pharma industry is seeing an increased focus on strengthening data and knowledge management in R&D pipelines to make the most of discovery data. Researchers are seeking new techniques to manage complex early stage discovery portfolios and for library optimisation. On day two our Congress features an exciting stream dedicated to supporting innovation with informatics tools in which we will explore new data analysis and integration platforms, as well as ideas for efficient data exchange and pre-competitive collaboration. Day two will also host discussions about the latest research in the discovery chemistry field, with exciting case studies covering computational tools for gene editing and drug design as well as fragment based drug discovery case studies.
